Is Cybin Inc. (CYBN) a Buy, Sell, or Hold?
AMEX : CYBN
Cybin Inc.
$8.28 USD
$0.1 (1.22%)
- Volume
- 716.53K
- Average Volume
- 874.38K
- Market Capitalization
- $413.02M
- P/E Ratio
- -2.26
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $10.72
- Year Low
- $4.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.58
Company Overview
AMEX
Eric So
Biotechnology
Healthcare
CYBN
50
CA
USD
Liquidity Metrics
0.21
8.58
8.58
6.27
0.00
Sales & Valuation
-$
0.00
1.44
-5.23
-3.26
Profitability
-$0.61
-$113.14M
0.00%
0.00%
-50.68%
-45.44%
P/E Metrics
-2.26
0.06
0.06
Analyst Price Target & Rating
0/5
4 Analysts
%
Poll Results
About Cybin Inc. (AMEX:CYBN) Stock
Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada. ...
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
2026-07-15 11:34:00
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...
CleanSpark shares surge after company secures $6.6B data center lease agreement
2026-07-14 07:53:00
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
2026-07-14 07:20:00
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
Cybin: A Speculative Bet On Their Pivotal Depression Readout
2026-06-27 10:40:00
Cybin operates as Helus Pharma, which is a clinical-stage biotech built around deuterated serotonergic therapies for depression and anxiety. I believe their main value driver is HLP003, which will report in Q4 2026 its Phase 3 APPROACH readout. HELP also recently raised funds in June 2026, and they don't have financial debt. So, they should have enough resources to reach this important milestone later this year.
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
2026-05-13 08:00:00
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the
Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)
2026-04-21 15:51:32
I am upgrading Cybin Inc. to Buy, driven by recent regulatory and clinical tailwinds that favor its lead candidate, HLP003. HELP is positioned to benefit from expedited FDA pathways and increased institutional support, particularly for major depressive disorder and PTSD indications. The market undervalues HELP, trading near cash value with a 0.84x forward price-to-book and an $85M EV versus $195M in cash.
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
2026-04-21 09:48:00
FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...
Psychedelics stocks rise after Trump order expands research, access pathways
2026-04-20 05:56:00
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...
Frequently Asked Questions
-
What is the current Cybin Inc. (CYBN) stock price?
-
Cybin Inc.(AMEX:CYBN) stock price is $8.28 in the last trading session. During the trading session, CYBN stock reached the peak price of $10.7199 while $4.81 was the lowest point it dropped to. The percentage change in CYBN stock occurred in the recent session was 1.22% while the dollar amount for the price change in CYBN stock was $0.1.
-
CYBN's industry and sector of operation?
-
The AMEX listed CYBN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CYBN?
-
George Tziras | Chief Business Officer
Gabriel Fahel | Chief Legal Officer & Corporate Secretary
Greg Cavers | Chief Financial Officer
Paul Glavine | Co-Founder, Chief Growth Officer & Director
Lori Challenger | Chief Compliance, Ethics & Administrative Officer -
How many employees does CYBN have?
-
Number of CYBN employees currently stands at 50. CYBN operates from 100 King Street West, Toronto, ON M5X 1C9, CA.
-
Link for CYBN official website?
-
Official Website of CYBN is: https://www.cybin.com
-
How do I contact CYBN?
-
CYBN could be contacted at phone #908 764 8385 and can also be accessed through its website. CYBN operates from 100 King Street West, Toronto, ON M5X 1C9, CA.
-
How many shares of CYBN are traded daily?
-
The average number of CYBN shares traded daily for last 3 months was 874.38K.
-
What is the market cap of CYBN currently?
-
The market value of CYBN currently stands at $413.02M with its latest stock price at $8.28